Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on VYNE Therapeutics (VYNE – Research Report). The associated price target remains the same with $6.00. Discover the ...

ANI Video “Aapne Jo Izzat Kamai Hai …” PM Modi’s emotional words make Indian workers ‘feel proud’ in Kuwait Posted: 22 December 2024 | Last updated: 22 December 2024 Kuwait, December ...

The box office figures are compiled from various sources and our own research. The figures can be approximate and Bollywood Hungama does not make any claims about the authenticity of the data ...

In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report), with a price target of $75.00. Pick the best ...

Lifesci Capital analyst R. Katkhuda now anticipates that the company will post earnings per share of ($1.35) for the year, up from their previous estimate of ($1.47). The consensus estimate for ...